Search results for " medulloblastoma"

showing 8 items of 8 documents

Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma

2018

Recurrent mutations in chromatin modifiers are specifically prevalent in adolescent or adult patients with Sonic hedgehog-associated medulloblastoma (SHH MB). Here, we report that mutations in the acetyltransferase CREBBP have opposing effects during the development of the cerebellum, the primary site of origin of SHH MB. Our data reveal that loss of Crebbp in cerebellar granule neuron progenitors (GNPs) during embryonic development of mice compromises GNP development, in part by downregulation of brain-derived neurotrophic factor (Bdnf). Interestingly, concomitant cerebellar hypoplasia was also observed in patients with Rubinstein-Taybi syndrome, a congenital disorder caused by germline mu…

0301 basic medicineCerebellumCrebbp protein mousemetabolism [Cerebellar Neoplasms]acetyltransferase; cerebellum; CREBBP; development; Rubinstein-Taybi syndrome; SHH medulloblastomagenetics [Hedgehog Proteins]MiceNeurotrophic factorsmetabolism [CREB-Binding Protein]Mice KnockoutNeuronsRubinstein-Taybi Syndromepathology [Rubinstein-Taybi Syndrome]CREBBPCREB-Binding ProteinPhenotypegenetics [CREB-Binding Protein]3. Good healthpathology [Cerebellar Neoplasms]acetyltransferasePhenotypemedicine.anatomical_structuregenetics [Rubinstein-Taybi Syndrome]Femalemetabolism [Hedgehog Proteins]Signal TransductionSHH medulloblastomaAdultcerebellumBiologyGeneral Biochemistry Genetics and Molecular BiologyCREBBP; Rubinstein-Taybi syndrome; SHH medulloblastoma; acetyltransferase; cerebellum; development.03 medical and health sciencesGermline mutationAcetyltransferasesmetabolism [Medulloblastoma]medicineAnimalsHumansgenetics [Cerebellar Neoplasms]Hedgehog Proteinsddc:610Cerebellar NeoplasmsdevelopmentMolecular BiologyMedulloblastomaRubinstein–Taybi syndromegenetics [Medulloblastoma]metabolism [Rubinstein-Taybi Syndrome]pathology [Medulloblastoma]Cell Biologymedicine.disease030104 developmental biologyMutationphysiology [CREB-Binding Protein]Cancer researchSHH protein humanCerebellar hypoplasia (non-human)metabolism [Acetyltransferases]CREBBP protein humanMedulloblastomaDevelopmental BiologyCongenital disorderDevelopmental Cell
researchProduct

Different immunohistochemical levels of Hsp60 and Hsp70 in a subset of brain tumors and putative role of Hsp60 in neuroepithelial tumorigenesis

2013

In this work we analysed, by immunohistochemistry, a series of brain tumors to detect the levels and cellular distribution of Hsp60 and Hsp70. We found that Hsp60 levels were significantly higher than those of Hsp70 in neuroepithelial tumors, while levels of both molecules were not significantly different from each other in meningeal neoplasms. In particular, Hsp60 immunopositivity was present mainly at the cytoplasmic level, while Hsp70 immunopositivity was found both in the cytoplasm and in the nucleus of tumor cells. The levels of these molecules in healthy control cells were always very low. Finally, Hsp60 and Hsp70 levels did not correlate with the different types (WHO grade) of neopla…

AdultMalePathologymedicine.medical_specialtyanimal structuresHistologyAdolescentNeuroepithelial CellsBiophysicschemical and pharmacologic phenomenaBiologymedulloblastomamedicine.disease_causemeningiomacomplex mixturesHsp60 Hsp70 astrocytoma glioblastoma multiformae medulloblastoma meningiomaHsp70Meningeal NeoplasmsmedicineHumansHSP70 Heat-Shock ProteinsMeningeal NeoplasmChildastrocytomalcsh:QH301-705.5AgedAged 80 and overMedulloblastomaHsp60 Hsp70 astrocytoma glioblastoma multiformae medulloblastoma meningioma.Brain NeoplasmsBrief ReportfungiAstrocytomaChaperonin 60Cell BiologyMiddle AgedHsp60medicine.diseaseImmunohistochemistryNeoplasms NeuroepithelialNeuroepithelial cellglioblastoma multiformaelcsh:Biology (General)Tumor progressionChild PreschoolCancer cellImmunohistochemistryFemaleCarcinogenesisEuropean Journal of Histochemistry
researchProduct

Etoposide Treatment in Recurrent Medulloblastoma

1994

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosine arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60+ months. Etoposide seems to be an active agent in medulloblastoma.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentNeutropeniaGastroenterologyRecurrencePrednisoneInternal medicinemedicineHumansSpinal Cord NeoplasmsNeoplasm MetastasisChildEtoposideEtoposideMedulloblastomaChemotherapyBrain Neoplasmsbusiness.industryGeneral MedicineRecurrent MedulloblastomaPrognosismedicine.diseaseFrontal LobeSurgeryTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthToxicityFemaleMethotrexateNeurology (clinical)Tomography X-Ray ComputedbusinessMedulloblastomamedicine.drugNeuropediatrics
researchProduct

A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma

2012

Due to the lacking specificity of symptoms making a correct diagnosis can be a challenge in children with medulloblastoma. This can lead to prediagnostic symptomatic intervals (PSIs) of several weeks to months. It is unknown whether the length of the PSI is associated with an inferior survival outcome in this population.To study the association of PSI with disease stage at diagnosis, tumour control and survival in children with medulloblastoma, prospectively collected data on PSI, clinical, and biological features were analysed in 224 patients diagnosed at the age of 3-18 years and treated within the prospective randomised multicentre trial HIT'91.Patients with lower-stage disease tended to…

MaleCancer ResearchPediatricsmedicine.medical_specialtyDelayed DiagnosisTime FactorsAdolescentPopulation610 Medicine & healthDiseaselaw.inventionRandomized controlled triallawChildhood MedulloblastomaHumansMedicine1306 Cancer ResearchAge of OnsetStage (cooking)Cerebellar NeoplasmsChildeducationMedulloblastomaeducation.field_of_studybusiness.industryCancerPrognosismedicine.diseaseOncology10036 Medical ClinicChild PreschoolFemale2730 OncologyAge of onsetbusinessMedulloblastomaEuropean Journal of Cancer
researchProduct

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters

2016

Purpose To assess an intensified treatment in the context of clinical and biologic risk factors in metastatic medulloblastoma. Patients and Methods Patients (4 to 21 years old, diagnosed between 2001 and 2007) received induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy. Subgroup status and other biologic parameters were assessed. Results In 123 eligible patients (median age, 8.2 years old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were 62% (95% CI, 52 to 72) and 74% (95% CI, 66 to 82), respectively. OS was superior compared with the precedent HIT ’91 trial. The 5-year EFS and OS wer…

MaleOncologyCancer Researchmedicine.medical_specialtyAdolescentPopulationMedizinMaintenance ChemotherapyAnaplastic MedulloblastomaYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineProspective StudiesNeoplasm MetastasisCerebellar NeoplasmsChildeducationSurvival rateMedulloblastomaeducation.field_of_studybusiness.industryHazard ratioInduction chemotherapyPrognosismedicine.diseaseCombined Modality TherapySurgerySurvival RateRegimenExact testOncologyAustriaChild Preschool030220 oncology & carcinogenesisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessSwitzerland030217 neurology & neurosurgeryMedulloblastomaJournal of Clinical Oncology
researchProduct

Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature

2020

Background/aim Medulloblastoma is a rare tumor of adult age, while it occurs more frequently in children. Given the rarity, there is a lack of evidence for the treatment of recurrent disease. Few data are available about salvage re-irradiation collecting very heterogeneous series. Case report A 51-year-old male presented with headache, nausea, double vision, and gait disorders. A contrast-enhanced brain-MRI showed the presence of multifocal medulloblastoma. After surgery, adjuvant craniospinal radiotherapy was performed, chemotherapy was stopped due to toxicity. After 27 months, a new MRI and a Methionine-PET revealed a late pontocerebellar relapse; multidisciplinary board decided for a SBR…

MaleRe-IrradiationCancer Researchmedicine.medical_specialtyAdult MedulloblastomaNauseamedicine.medical_treatmentDiseaseGeneral Biochemistry Genetics and Molecular BiologyRe-Irradiation03 medical and health sciences0302 clinical medicineRecurrent diseaseHumansMedicineEffective treatmentCerebellar NeoplasmsSalvage TherapyPharmacologyMedulloblastomaChemotherapybusiness.industryAdult patientsMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTumor BurdenTreatment OutcomePositron-Emission Tomography030220 oncology & carcinogenesisRadiologymedicine.symptombusinessResearch ArticleMedulloblastomaIn Vivo
researchProduct

Involvement of the long arm of chromosome 9 in medulloblastoma in an adult.

1997

Abstract Medulloblastoma is the most common primitive neuroectodermal tumor (PNET) in children, but is very rare in adults. An isochromosome for the long arms of 17, i(17q), is found in about 30% of pediatric cases. Cytogenetic studies in adults are very scarce; only six cases have been described cytogenetically: three cases had normal karyotype, two were studied partially, and another presented only two clonal structural anomalies: del(9)(q12) and del(11)(q22). We studied the chromosomes from medulloblastoma in a 27-year-old woman and found one hypotetraploid stemline with clonal alterations. In the structural anomalies, chromosomes 3, 9, 12, and i(17q) were involved. Chromosome 9 presente…

MedulloblastomaAdultCancer Researchmedicine.medical_specialtyPathologyAdult MedulloblastomaIsochromosomeCytogeneticsChromosome 9KaryotypeAnatomyBiologymedicine.diseasePrimitive neuroectodermal tumorKaryotypingGeneticsmedicineHumansHistopathologyFemaleChromosome DeletionCerebellar NeoplasmsChromosomes Human Pair 9Molecular BiologyMedulloblastomaCancer genetics and cytogenetics
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

2005

The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five…

medicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentIntelligenceBrain tumorNeuropsychological TestsCarboplatinchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCerebellar NeoplasmsCyclophosphamideEtoposideEtoposideProportional Hazards ModelsMedulloblastomaPostoperative CareChemotherapyAnalysis of Variancebusiness.industryDesmoplastic medulloblastomaRemission InductionInfantGeneral Medicinemedicine.diseaseSurvival AnalysisCarboplatinSurgeryMethotrexatechemistryChemotherapy AdjuvantVincristineChild PreschoolNeoplasm Recurrence Localbusinessmedicine.drugFollow-Up StudiesMedulloblastomaThe New England journal of medicine
researchProduct